Kaken Pharmaceutical Co Ltd 2018 Integrated Report
The report integrates KAKEN's financial, environmental, and social reporting into one corporate report prepared with reference to the IIRC disclosure framework. For FY2017, the company reported consolidated net sales of ¥98,430 million and continued to focus on its pharmaceuticals-led business, including Clenafin and its R&D pipeline. Environmental highlights for the Shizuoka site and Kyoto Drug Research Center included 26,227 t-CO2 emissions, 2,603 tons of waste discharged, and a 99.2% waste recycling rate. The report also records 1,389 consolidated employees as of March 31, 2018.
Company: Kaken Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2018
Type: Integrated Report
Pages: 72
Back to company
Kaken Pharmaceutical Co Ltd
Corporate Report
The report integrates KAKEN's financial, environmental, and social reporting into one corporate report prepared with reference to the IIRC disclosure framework. For FY2017, the company reported consolidated net sales of ¥98,430 million and continued to focus on its pharmaceuticals-led business, including Clenafin and its R&D pipeline. Environmental highlights for the Shizuoka site and Kyoto Drug Research Center included 26,227 t-CO2 emissions, 2,603 tons of waste discharged, and a 99.2% waste recycling rate. The report also records 1,389 consolidated employees as of March 31, 2018.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Apr 1, 2017 - Mar 31, 2018
Fiscal Year
2018
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Employees